Cancer survival linked to cardiovascular hormone/peptide levels
the ONA take:
Cardiovascular biomarkers such as high circulating levels of cardiovascular hormones/peptides in patients with cancer are linked to shorter survival, according to research published online in Heart.
In this study, researchers sought to determine whether the cancer itself affects levels of cardiovascular hormones/peptides.
The researchers assessed circulating levels of several cardiovascular hormones; proteins indicative of inflammation; and high sensitive troponin (hsTNT), a chemical that regulates heart muscle contractions, in 555 people with a first cancer diagnosis.
None of the participants had yet undergone any drug or radiotherapy treatments that might have damaged their heart tissue. The participants were tracked for an average of 25 months.
Almost one-third of the participants died during the monitoring period. Analysis of their blood samples showed that all the hormones measured and hsTNT increased in tandem with disease severity, sometimes to levels 100 times higher than expected.
The researchers report that their findings suggest that these biomarkers were indicative of heart damage not yet clinically evident, but directly linked to the cancer progression.
Furthermore, the findings suggest that the benefits of heart failure drugs for cancer patients may extend beyond helping to reduce cardiovascular side effects of cancer treatment.
Cardiovascular biomarkers such as high circulating levels of cardiovascular hormones/peptides in cancer are linked to shorter survival.
Sign Up for Free e-newsletters
- Hodgkin Lymphoma Survivorship Marked by Periods of Actionable Distress
- Medication, Vaccination Uptake Improved by Involving Pharmacists in Elder Cancer Care
- Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis
- Stem Cell Transplantation Superior to Chemotherapy for Relapsed/Refractory DLBCL, Follicular Lymphoma
- Study Reveals Relationship of Sleep Duration, Diabetes Risk in Cancer Survivors
- Navigating Prostate Cancer: A Patient's Experience From Diagnosis to Survivor
- Cell Phones and Cancer Risk (Fact Sheet)
- How Likely Are Oncologists to Refer for Palliative Care? Depends on Their Age
- Use of Corticosteroids With PD-1 or PD-L1 Inhibitors Associated With Poorer Outcomes in NSCLC
- Chemoimmunotherapy Increases Survival in Triple-Negative Breast Cancer
- Risk for Colon Cancer, Osteogenic Sarcoma Higher With Presence of Diamond-Blackfan Anemia
- G-CSF Support Increases Overall Survival, But Risk of Secondary Malignancies Also Higher
- Report From Childhood Cancer Survivor Study Identifies Long-Term Risks for VTE
- The Effect of Intravenous Hydration Strategy on Plasma Methotrexate Clearance During Intravenous High-dose Methotrexate Administration in Pediatric Oncology Patients
- Outcomes Worse for Minimally Invasive Hysterectomy vs Open Surgery
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|